La b-Talassemia Omozigote - Associazione Talassemici di Torino
La b-Talassemia Omozigote - Associazione Talassemici di Torino
La b-Talassemia Omozigote - Associazione Talassemici di Torino
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Maria Maddalena Atzeni, Antonio Masala <strong>La</strong> β-talassemia omozigote<br />
33. Propper RD, Cooper B et al.: Continuous subcutaneus administration of<br />
desterrioxamine in patients with iron ooverload. N Engl J Med 1977;<br />
297: 418-423.<br />
34. World Health Organization. Working group on comunity control of<br />
here<strong>di</strong>tary anaemias: a short guide to the management of thalassemia.<br />
Thalassemia Today. Proc 2 nd Me<strong>di</strong>t Meeting Thal. Ed G. Sirchia e A.<br />
Zanella, Milano 1987, pag 635<br />
35. Cohen A.: Management of iron overload in the pe<strong>di</strong>atric patient. In:<br />
Haematol Oncol Clin north Am 521, 1987.<br />
36. Cazzola M, Bergamaschi G et al.: The origin of serum ferritin in acquired<br />
transfusional iron overload in adults. Stu<strong>di</strong>es with concanavalin Asepharose<br />
absorption. Haematologica 1982; 67: 817-824.<br />
37. Cazzola M, Bergamaschi G. et al: Internal <strong>di</strong>stribution of excess iron and<br />
sources of serum ferritin in patients with β-thalassemia. Scand J Haemat<br />
1993; 30: 289-297.<br />
38. Baynes R. Bezwodaw, Bothwell T, Khan Q, Mansoor N.: The non-immune<br />
infiammatory response: serial changes in plasma iron, iron-bin<strong>di</strong>ng<br />
capacity, lactoferrin, ferritin and C-reactive protein. Scand J Clin <strong>La</strong>b<br />
Invest 1986; 27: 277-279.<br />
39. Hershkoc C, Link G, Cabantchik ZI.: Mechanism of iron toxicity and<br />
chelation. 6 th International Conference on Thalassemia and Haemoglobinopaties,<br />
5-10 April 1997, St Paul’s Bay, Malta, Abstract 256.<br />
40. Nancy F, Olivieri NF, Brittenham GM.: Iron-chelating therapy and the<br />
treattament of thalassemia. Blood 1997; 89:739-761.<br />
41. Nyman CB, Chapman CL.: Use of central venous access for iron chelation<br />
therapy. Ann NYAcad Sci 1990; 612: 579-581.<br />
42. Kontoghiorghes GJ.: Design properties and effective use of the oral chelator<br />
L 1 and other β-ketohydroxypyri<strong>di</strong>nes in the treatment of transfusional<br />
iron overload in thalassemia. Ann NYAcad Sci 1990; 612: 339-348.<br />
43. Al-Refaie SN, Sheppard LN, Nortey P, Wonke B, Hoffbrand A : ,<br />
Pharmacochinetics of the oral iron chelator Deferiprone (L1) in patients<br />
with iron overload. Br J Haematol 1995; 89: 403-406.<br />
Caleidoscopio<br />
39
Change language